Etanercept Combined With Systemic Drugs or Phototherapy for Treatment of Psoriasis

Ara, Mariano; Gracia, T.; Pastushenko, E.

doi:10.1016/j.adengl.2015.01.003

Cited by 2 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies also suggest that down‐titration may be possible without compromising disease control . Furthermore, etanercept can also be used in combination therapy; the combination of etanercept plus MTX or acitretin has shown benefit in patients inadequately responding to monotherapy and UVB–etanercept combination treatment has proven to have a synergistic effect, although usage should be reserved for selected cases owing to potential carcinogenicity concerns …”

Section: Etanercept Overviewmentioning

confidence: 99%

Treatment of psoriasis with etanercept: the typical patient profile

Prinz

Puig

Girolomoni

2016

Acad Dermatol Venereol

View full text Add to dashboard Cite

The chronic nature of psoriasis means that patients often require lifetime treatment. Over this time, treatment frequently has to be adapted to meet variable demands resulting from changes in life course and life events. Biological drugs used to treat psoriasis vary in their dosing regimens, convenience and flexibility. Dermatologists need to understand which biologic agent is best suited for each individual patient. A wealth of evidence supports the safe and effective use of etanercept, which offers a rapid and sustained response, flexibility of dosing, maintenance of response after dose reduction or interruption, and efficacy against non-skin manifestations such as psoriatic arthritis. An expert panel met to agree the typical patient profile of a psoriasis patient treated with etanercept, the main benefits of etanercept in psoriasis, and the patient group most likely to benefit from its use. They agreed that flexibility of dosing, the potential to individualize therapy by stopping and starting treatment while maintaining efficacy, and the possibility of cost saving through the use of flexible treatment regimens were important benefits supporting the use of etanercept in many patients with psoriasis.

show abstract

Section: Etanercept Overviewmentioning

confidence: 99%

Treatment of psoriasis with etanercept: the typical patient profile

Prinz

Puig

Girolomoni

2016

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Annoying Psoriasis and Atopic Dermatitis: A Narrative Review

Chen

Hsu

et al. 2022

IJMS

View full text Add to dashboard Cite

Skin is an important organ that mainly functions as a barrier. Skin diseases can damage a person’s self-confidence and reduce their willingness to socialize, as well as their social behavior and willingness. When the skin appearance is abnormal, in addition to affecting the quality of life, it often leads to personal, social, and psychological dysfunction and even induces depression. Psoriasis and atopic dermatitis are common chronic skin diseases. Their prevalence in the world is 3–10%, and there is an increasing trend year by year. These congenital or acquired factors cause the dysfunction of the immune system and then destroy the barrier function of the skin. Because these patients are flooded with a variety of inflammatory mediators, this causes skin cells to be in chronic inflammation. Therefore, psoriasis and atopic dermatitis are also considered systemic chronic inflammatory diseases. In the healthcare systems of developed countries, it is unavoidable to spend high costs to relieve symptoms of psoriasis and atopic dermatitis patients, because psoriasis and atopic dermatitis have a great influence on individuals and society. Giving a lot of attention and developing effective treatment methods are the topics that the medical community must work on together. Therefore, we used a narrative review manuscript to discuss pathogenesis, clinical classification, incidence, and treatment options, including topical medication, systemic therapeutics, immunosuppressive medication for psoriasis, and atopic dermatitis, as well as also comparing the differences between these two diseases. We look forward to providing readers with comprehensive information on psoriasis and atopic dermatitis through this review article.

show abstract

Etanercept Combined With Systemic Drugs or Phototherapy for Treatment of Psoriasis

Cited by 2 publications

References 40 publications

Treatment of psoriasis with etanercept: the typical patient profile

Treatment of psoriasis with etanercept: the typical patient profile

Annoying Psoriasis and Atopic Dermatitis: A Narrative Review

Contact Info

Product

Resources

About